
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Cancer Research, Vol 4, Issue 1 13-20, Copyright © 1998 by American Association for Cancer Research
ARTICLES |
JR Grandis, DJ Tweardy and MF Melhem
Department of Otolaryngology, University of Pittsburgh School of Medicine, Pennsylvania, USA.
The development of head and neck squamous cell carcinoma occurs as a result of the accumulation of genotypic and phenotypic alterations in the upper aerodigestive tract mucosa. Up-regulation of epidermal growth factor receptor (EGFR) and its ligand, transforming growth factor alpha (TGF-alpha), have been identified previously as early events in head and neck carcinogenesis. To determine the timing of increased TGF-alpha and EGFR protein expression in the development of head and neck cancer, we examined progressive mucosal dysplasias from three distinct and complimentary patient groups: (a) samples from patients with lesions demonstrating different degrees of dysplasia (n = 22) compared with mucosa samples from gender and age-matched controls (n = 8); (b) patients with lesions demonstrating different degrees of dysplasia at a single time point (n = 3); and (c) patients who progressed over several years to invasive cancer at the site of dysplasia (n = 7). Immunohistochemical analysis with monoclonal antibodies specific for TGF-alpha and EGFR were used to detect protein expression in all specimens. Protein levels were further quantitated using a computerized image analysis system. In all three groups, we found that TGF-alpha protein levels were elevated in mild dysplasia compared with control normal mucosa and were not further modulated with increasing degrees of dysplasia. In contrast, EGFR levels were relatively low in mild dysplasia and increased with higher degrees of dysplasia. These findings indicate that up-regulation of TGF-alpha and EGFR are distinct events both chronologically and, possibly, mechanistically in the pathogenesis of head and neck squamous cell carcinoma.
This article has been cited by other articles:
![]() |
K. K. Ang Multidisciplinary Management of Locally Advanced SCCHN: Optimizing Treatment Outcomes Oncologist, August 1, 2008; 13(8): 899 - 910. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. N. William Jr. and V. A. Papadimitrakopoulou Identification of High-risk Cohorts for Head and Neck Cancer Prevention Based on Tissue Markers LOH and cyclin D1 ASCO Educational Book, January 1, 2008; 2008(1): 66 - 68. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Temam, H. Kawaguchi, A. K. El-Naggar, J. Jelinek, H. Tang, D. D. Liu, W. Lang, J.-P. Issa, J. J. Lee, and L. Mao Epidermal Growth Factor Receptor Copy Number Alterations Correlate With Poor Clinical Outcome in Patients With Head and Neck Squamous Cancer J. Clin. Oncol., June 1, 2007; 25(16): 2164 - 2170. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Lippman and J. J. Lee Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res., March 15, 2006; 66(6): 2893 - 2903. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Pfister, Y. B. Su, D. H. Kraus, S. L. Wolden, E. Lis, T. B. Aliff, A. J. Zahalsky, S. Lake, M. N. Needle, A. R. Shaha, et al. Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm J. Clin. Oncol., March 1, 2006; 24(7): 1072 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Choe, X. Zhang, H. J. C. Shin, D. M. Shin, and Z. Chen Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer Mol. Cancer Ther., September 1, 2005; 4(9): 1448 - 1455. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sudbo Novel Management of Oral Cancer: A Paradigm of Predictive Oncology Clin. Med. Res., November 1, 2004; 2(4): 233 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kagawa, T. Sano, N. Ishibashi, M. Hashimoto, M. Okuno, H. Moriwaki, R. Suzuki, H. Kohno, and T. Tanaka An acyclic retinoid, NIK-333, inhibits N-diethylnitrosamine-induced rat hepatocarcinogenesis through suppression of TGF-{alpha} expression and cell proliferation Carcinogenesis, June 1, 2004; 25(6): 979 - 985. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Rhee, F. R. Khuri, and D. M. Shin Advances in Chemoprevention of Head and Neck Cancer Oncologist, June 1, 2004; 9(3): 302 - 311. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-H. Tang, B. Knudsen, D. Bemis, S. Tickoo, and L. J. Gudas Oral Cavity and Esophageal Carcinogenesis Modeled in Carcinogen-Treated Mice Clin. Cancer Res., January 1, 2004; 10(1): 301 - 313. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Xi, Q. Zhang, W. E. Gooding, T. E. Smithgall, and J. R. Grandis Constitutive Activation of Stat5b Contributes to Carcinogenesis in Vivo Cancer Res., October 15, 2003; 63(20): 6763 - 6771. [Abstract] [Full Text] [PDF] |
||||
![]() |
A-P. Meert, J-M. Verdebout, B. Martin, V. Ninane, F. Feoli, and J-P. Sculier Epidermal growth factor receptor expression in pre-invasive and early invasive bronchial lesions Eur. Respir. J., April 1, 2003; 21(4): 611 - 615. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. McGregor, A. Muntoni, J. Fleming, J. Brown, D. H. Felix, D. G. MacDonald, E. K. Parkinson, and P. R. Harrison Molecular Changes Associated with Oral Dysplasia Progression and Acquisition of Immortality: Potential for Its Reversal by 5-Azacytidine Cancer Res., August 15, 2002; 62(16): 4757 - 4766. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. O'Shaughnessy, G. J. Kelloff, G. B. Gordon, A. J. Dannenberg, W. K. Hong, C. J. Fabian, C. C. Sigman, M. M. Bertagnolli, S. P. Stratton, S. Lam, et al. Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development : Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia Clin. Cancer Res., February 1, 2002; 8(2): 314 - 346. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. I. Song, M. N. Lango, J. D. Hwang, S. D. Drenning, Q. Zeng, W. W. Lamph, and J. R. Grandis Abrogation of Transforming Growth Factor-{alpha}/Epidermal Growth Factor Receptor Autocrine Signaling by an RXR-selective Retinoid (LGD1069, Targretin) in Head and Neck Cancer Cell Lines Cancer Res., August 1, 2001; 61(15): 5919 - 5925. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Robert, M. P. Ezekiel, S. A. Spencer, R. F. Meredith, J. A. Bonner, M. B. Khazaeli, M. N. Saleh, D. Carey, A. F. LoBuglio, R. H. Wheeler, et al. Phase I Study of Anti-Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer J. Clin. Oncol., July 1, 2001; 19(13): 3234 - 3243. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Bancroft, Z. Chen, G. Dong, J. B. Sunwoo, N. Yeh, C. Park, and C. Van Waes Coexpression of Proangiogenic Factors IL-8 and VEGF by Human Head and Neck Squamous Cell Carcinoma Involves Coactivation by MEK-MAPK and IKK-NF-{{kappa}}B Signal Pathways Clin. Cancer Res., February 1, 2001; 7(2): 435 - 442. [Abstract] [Full Text] |
||||
![]() |
J. R. Grandis, D. M. Falkner, M. F. Melhem, W. E. Gooding, S. D. Drenning, and P. A. Morel Human Leukocyte Antigen Class I Allelic and Haplotype Loss in Squamous Cell Carcinoma of the Head and Neck: Clinical and Immunogenetic Consequences Clin. Cancer Res., July 1, 2000; 6(7): 2794 - 2802. [Abstract] [Full Text] |
||||
![]() |
R. E. Favoni and A. De Cupis The Role of Polypeptide Growth Factors in Human Carcinomas: New Targets for a Novel Pharmacological Approach Pharmacol. Rev., June 1, 2000; 52(2): 179 - 206. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Zeng, D. C. Smith, T. J. Suscovich, W. E. Gooding, D. L. Trump, and J. R. Grandis Determination of Intermediate Biomarker Expression Levels by Quantitative Reverse Transcription-Polymerase Chain Reaction in Oral Mucosa of Cancer Patients Treated with Liarozole Clin. Cancer Res., June 1, 2000; 6(6): 2245 - 2251. [Abstract] [Full Text] |
||||
![]() |
J. R. Grandis, S. D. Drenning, Q. Zeng, S. C. Watkins, M. F. Melhem, S. Endo, D. E. Johnson, L. Huang, Y. He, and J. D. Kim Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo PNAS, April 11, 2000; 97(8): 4227 - 4232. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |